PL3180362T3 - Przeciwciała swoiste dla MMP9 - Google Patents
Przeciwciała swoiste dla MMP9Info
- Publication number
- PL3180362T3 PL3180362T3 PL15749818T PL15749818T PL3180362T3 PL 3180362 T3 PL3180362 T3 PL 3180362T3 PL 15749818 T PL15749818 T PL 15749818T PL 15749818 T PL15749818 T PL 15749818T PL 3180362 T3 PL3180362 T3 PL 3180362T3
- Authority
- PL
- Poland
- Prior art keywords
- mmp9
- antibodies specific
- antibodies
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180765.1A EP2985296A1 (en) | 2014-08-13 | 2014-08-13 | Antibodies specific for MMP9 |
| EP15749818.9A EP3180362B1 (en) | 2014-08-13 | 2015-08-13 | Antibodies specific for mmp9 |
| PCT/EP2015/068645 WO2016023979A1 (en) | 2014-08-13 | 2015-08-13 | Antibodies specific for mmp9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3180362T3 true PL3180362T3 (pl) | 2020-06-15 |
Family
ID=51301193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15749818T PL3180362T3 (pl) | 2014-08-13 | 2015-08-13 | Przeciwciała swoiste dla MMP9 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10364296B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2985296A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6856523B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170041222A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106573984A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015303183B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017002703A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2956986A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2784271T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX380238B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3180362T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2714043C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016023979A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170306050A1 (en) | 2016-04-08 | 2017-10-26 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| BR112019012253A2 (pt) | 2016-12-16 | 2020-01-28 | Centre Hospitalier Univ Bordeaux | inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação |
| BR112019025097A2 (pt) * | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | imunoglobulinas de ligação a mmp13 |
| US20200124604A1 (en) * | 2017-06-30 | 2020-04-23 | National Institutes Of Biomedical Innovation, Health And Nutrition | Biomarker for detecting colorectal cancer |
| KR102657653B1 (ko) | 2017-07-18 | 2024-04-16 | 다이이찌 산쿄 가부시키가이샤 | 활성형 mmp-9 결합 펩티드 |
| US12053523B2 (en) | 2017-12-13 | 2024-08-06 | North Carolina State University | Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use |
| ES2917629T3 (es) * | 2018-01-22 | 2022-07-11 | Liquid Biopsy Res Llc | Métodos para la detección del cáncer de colon y monitorización del tratamiento |
| CN108277214B (zh) * | 2018-02-23 | 2021-07-06 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
| EP3972644A4 (en) * | 2019-05-21 | 2024-01-10 | The Regents Of The University Of California | MMP-9 ANTIBODIES AND METHODS OF USE THEREOF |
| CN110885375B (zh) * | 2019-12-20 | 2021-07-02 | 南京融捷康生物科技有限公司 | 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用 |
| WO2023278491A1 (en) * | 2021-06-28 | 2023-01-05 | Releviate, Llc | Mmp-9 antibodies and uses thereof |
| JP2023021745A (ja) * | 2021-08-02 | 2023-02-14 | 学校法人東京薬科大学 | がん転移抑制のための医薬組成物 |
| CN117327186B (zh) * | 2023-07-12 | 2024-03-12 | 北京达成生物科技有限公司 | 结合mmp3蛋白的双特异性抗体及其用途 |
| WO2025076280A1 (en) | 2023-10-05 | 2025-04-10 | Ashibio, Inc. | Methods and compositions for treating mmp-9 mediated disorders |
| CN117264069B (zh) * | 2023-11-23 | 2024-01-26 | 再少年(北京)生物科技有限公司 | 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用 |
| CN117820488B (zh) * | 2024-01-09 | 2024-10-01 | 首都医科大学附属北京朝阳医院 | 特异性针对mmp-9的抗体对、生物材料及其应用 |
| CN117964771B (zh) * | 2024-04-02 | 2024-06-21 | 智泽童康(广州)生物科技有限公司 | 一种特异性结合mmp7的抗体、mmp7检测试剂及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002235692A1 (en) * | 2001-02-23 | 2002-09-04 | Biophage Inc. | Methods and compositions for preventing and treating neutrophil-mediated diseases |
| GB0516069D0 (en) | 2005-08-04 | 2005-09-14 | Imp College Innovations Ltd | Pharmaceutical and use thereof |
| KR20090113908A (ko) * | 2007-02-23 | 2009-11-02 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물 |
| US8008445B2 (en) | 2008-03-03 | 2011-08-30 | Dyax Corp. | Metalloproteinase 9 binding proteins |
| AU2009221916A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| WO2010045388A2 (en) * | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis |
| US20110135573A1 (en) | 2009-09-03 | 2011-06-09 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| SI2608809T1 (sl) * | 2010-08-27 | 2019-08-30 | Gilead Biologics, Inc. | Protitelesa proti matriksu metaloproteinaze 9 |
| IN2014DN08011A (cg-RX-API-DMAC7.html) | 2012-02-29 | 2015-05-01 | Gilead Biologics Inc | |
| AU2013203619B2 (en) * | 2012-02-29 | 2015-02-26 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
-
2014
- 2014-08-13 EP EP14180765.1A patent/EP2985296A1/en not_active Withdrawn
-
2015
- 2015-08-13 RU RU2017107773A patent/RU2714043C2/ru active
- 2015-08-13 WO PCT/EP2015/068645 patent/WO2016023979A1/en not_active Ceased
- 2015-08-13 PL PL15749818T patent/PL3180362T3/pl unknown
- 2015-08-13 MX MX2017001959A patent/MX380238B/es unknown
- 2015-08-13 CN CN201580043394.1A patent/CN106573984A/zh active Pending
- 2015-08-13 BR BR112017002703-8A patent/BR112017002703A2/pt not_active IP Right Cessation
- 2015-08-13 ES ES15749818T patent/ES2784271T3/es active Active
- 2015-08-13 EP EP15749818.9A patent/EP3180362B1/en active Active
- 2015-08-13 AU AU2015303183A patent/AU2015303183B2/en not_active Ceased
- 2015-08-13 JP JP2017508053A patent/JP6856523B2/ja not_active Expired - Fee Related
- 2015-08-13 CA CA2956986A patent/CA2956986A1/en not_active Abandoned
- 2015-08-13 KR KR1020177004988A patent/KR20170041222A/ko not_active Ceased
- 2015-08-13 US US15/503,447 patent/US10364296B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN106573984A (zh) | 2017-04-19 |
| AU2015303183B2 (en) | 2021-01-28 |
| ES2784271T3 (es) | 2020-09-23 |
| US10364296B2 (en) | 2019-07-30 |
| EP3180362B1 (en) | 2020-02-05 |
| RU2714043C2 (ru) | 2020-02-11 |
| KR20170041222A (ko) | 2017-04-14 |
| EP2985296A1 (en) | 2016-02-17 |
| MX2017001959A (es) | 2017-05-04 |
| EP3180362A1 (en) | 2017-06-21 |
| JP6856523B2 (ja) | 2021-04-07 |
| WO2016023979A1 (en) | 2016-02-18 |
| BR112017002703A2 (pt) | 2018-02-27 |
| CA2956986A1 (en) | 2016-02-18 |
| RU2017107773A (ru) | 2018-09-13 |
| AU2015303183A1 (en) | 2017-02-16 |
| RU2017107773A3 (cg-RX-API-DMAC7.html) | 2018-09-13 |
| MX380238B (es) | 2025-03-12 |
| JP2017532005A (ja) | 2017-11-02 |
| US20170233495A1 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252004A0 (en) | Ether-substituted antibody | |
| IL250583A0 (en) | Anti-tigit antibodies | |
| SG11201703403TA (en) | Anti-tim-3 antibodies | |
| SG11201703346PA (en) | Anti-tim-3 antibodies | |
| IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
| PL3180362T3 (pl) | Przeciwciała swoiste dla MMP9 | |
| PL3221346T3 (pl) | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego | |
| IL252716A0 (en) | Anti-csf1r antibodies for the treatment of pvns | |
| GB201410520D0 (en) | Antibody | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| IL250374B (en) | Antibodies against ceramide | |
| IL248220A0 (en) | Anti- nme antibody | |
| IL247988A0 (en) | Antibodies against hpa–1a | |
| SG11201700922YA (en) | Anti-orai1 antibody | |
| SI3628731T1 (sl) | Novo protitelo proti presepsinu | |
| GB201417447D0 (en) | Improved immunoassay for pyrrolidinophenones | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201417614D0 (en) | Antibodies | |
| GB201414270D0 (en) | Antibodies | |
| GB201418776D0 (en) | Antibody | |
| GB201405775D0 (en) | Antibodies | |
| GB201401200D0 (en) | Antibodies | |
| GB201413745D0 (en) | Antibody | |
| GB201411319D0 (en) | Antibody |